Tongxinluo alleviated ox-LDL-induced hyperpermeability and restored disruptions of tight junction proteins ZO-1, occludin, and claudin1 via ERK1/2 activation in human umbilical vein endothelial cells.
Does Tongxinluo alleviate ox-LDL-induced hyperpermeability in Human Umbilical Vein Endothelial Cells?
Tongxinluo alleviates ox-LDL-induced endothelial hyperpermeability by restoring tight junction proteins via the ERK1/2 signaling pathway in vitro.
Vascular hyperpermeability resulting from distortion of endothelial junctions is associated with a number of cardiovascular diseases. Endothelial tight junction regulates the paracellular permeability of macromolecules, a function of Human Umbilical Vein Endothelial Cells (HUVEC) monolayers that can be regulated by oxidized Low-density Lipoprotein (ox‐LDL). However, the understanding of drug regulation of vascular hyperpermeability is so far limited. This study thus aimed to investigate the role of Tongxinluo (TXL) in the maintenance of the vascular endothelial paracellular permeability. Here, changes in permeability were determined by measuring the paracellular flux of FITC‐dextran 40000 (FD40), while protein expression and intercellular distribution were examined by western blot and immunofluorescence assay, respectively. We found that TXL alleviated the ox‐LDL‐induced increase in flux of FD40 and then reduced the hyperpermeability. Moreover, ox‐LDL‐induced disruptions of ZO‐1, occludin, and claudin1 were also restored. This is via the activation of ERK1/2 in the vascular endothelial cells. Our results provide insights into the molecular mechanism by which TXL alleviates ox‐LDL‐induced hyperpermeability and provide the basis for further investigations of TXL as regulators of vascular barrier function.
Chang et al. (Sun,) conducted a other in Vascular hyperpermeability. Tongxinluo (TXL) vs. ox-LDL alone was evaluated on Paracellular flux of FITC-dextran 40000 (FD40) and protein expression of tight junctions. Tongxinluo alleviated ox-LDL-induced hyperpermeability and restored disruptions of tight junction proteins ZO-1, occludin, and claudin1 via ERK1/2 activation in human umbilical vein endothelial cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: